by admin | Sep 10, 2019 | Licensing, Partnerships
Grünenthal, a global leader in pain management, and Mesoblast Limited, a world leader in allogeneic cellular medicines for inflammatory diseases, announced that they have entered into a strategic partnership to develop and commercialise MPC-06-ID, a Phase III...
by admin | Sep 7, 2019 | M&A - Buy-Out
The Boston-based company said it would acquire Semma Therapeutics, which is developing a stem cell-derived therapy and device for the disease. Preclinical data were announced in July, and clinical trials are planned for 2020. Vertex Pharmaceuticals is betting nearly...
